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Objectives. A recent trial showed the clinical beneﬁt of retreatment with varenicline in subjects failing on the
initial treatment, or relapsing after initial success. The objective of this study was to evaluate the cost-
effectiveness of retreatment with varenicline compared with other smoking cessation interventions.
Methods. A published Markov model was adapted to compare one quit attempt of varenicline followed by
retreatment to treatment/retreatment with nicotine replacement therapy (NRT), bupropion or placebo, and
with only 1 quit attempt of varenicline. Efﬁcacy was obtained from clinical trials. Incidence of smoking-related
diseases was based on published data. Cost of therapies and complications was obtained from databases and lit-
erature.Results. For 1000 smokers willing to quit, varenicline retreatment saves 275,000€, 118,000€, 316,000€ and
237,000€ compared to NRT, bupropion, placebo, or one single varenicline quit attempt respectively at lifetime
and from the healthcare payer perspective. The number of quality adjusted life years gained is 74, 63, 193 and
111 respectively. Sensitivity analyses showed the robustness of these ﬁndings.
Conclusion. This analysis suggests that in the long term, varenicline retreatment is a dominant intervention,
meaning both greater health gains and greater costs saved, over other possible interventions and therefore
should be considered as a standard option.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Smoking cessation (SC) therapies arewidely available in Europe and
many are reimbursed by public health care payers (Aubin et al., 2014).
Smoking cessation is aimed at preventing severe complications
associated with smoking, including COPD, lung cancer, coronary heart
diseases (CHD), stroke and asthma exacerbations. It is well established
that the lifespan of a smoker is shorter than that of a non-smoker,
with a difference of 6 to 10 years, on average, depending on the number
of cigarettes smoked (Van den Bruel et al., 2004).
Varenicline, nicotine replacement therapy (NRT) and bupropion are
the current standard pharmacological interventions to aid in smoking
cessation. In motivated subjects, starting a treatment with one of
these therapies is justiﬁed in association with behavioral counseling.
However, smoking cessation is difﬁcult and relapse is common among
individuals attempting to quit (Fiore et al., 2000).
A recent trial assessing the efﬁcacy of varenicline retreatment in sub-
jects unsuccessful after a ﬁrst attempt showed a success rate (deﬁned asix).
. This is an open access article undercontinuous abstinence from 9–52 weeks) of 20.1% (Gonzales et al.,
2014).
In the current health care environment, the need to allocate public
ﬁnances has increased the interest in cost-effectiveness research
(Annemans et al., 2011) and reimbursement of medicines does not
only require clinical effectiveness but also cost-effectiveness.
The objective of this study was to estimate the cost-effectiveness of
varenicline in retreatment compared to other possible retreatment op-
tions including no treatment, and retreatment with bupropion or NRT.
Methods
General aspects
The perspective of this analysis is the healthcare payer perspective:
the public health care payer (Rijksinstituut voor ziekte — en
invaliditeitsverzekering/Institut National d'Assurance Maladie-
Invalidité — RIZIV/INAMI) and the patient. This combined perspective
follows the recommendations of the Belgian Health Technology Assess-
ment (HTA) body KCE (Kenniscentrum—Centre d'expertise) (Cleemput
et al., 2012) and gives a complete picture of smoking cessation sincethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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perspective only direct health care costs are included.
Decision model
The Two-quit BENESCO (Beneﬁt of SmokingCessation onOutcomes)
model is based on an adaptation of the original BENESCO model, a
Markov model that was developed to assess the cost-effectiveness of
one quit attempt with smoking cessation interventions (Howard et al.,
2008). The BENESCO model simulates the incidence of smoking-
related morbidity and mortality over time and is an extension of the
HECOS (Health Economic Consequences of Smoking) model that was
used by the World Health Organization European Partnership Project
to reduce tobacco dependence (Orme et al., 2001). BENESCO model
has also been reviewed in various health technology assessments. This
model has been customized for various countries, including Belgium,
and the results have been widely published (Hoogendoorn et al.,
2008; Fernández de Bobadilla Osorio et al., 2008; Bolin et al., 2008;
Annemans et al., 2009; Igarashi et al., 2009; Bae et al., 2009; Linden
et al., 2010; Athanasakis et al., 2012; Lutz et al., 2012). These analyses
were also included in systematic reviews about the cost-effectiveness
of varenicline (Keating and Lyseng-Williamson, 2010; Zimovetz et al.,
2011; Mahmoudi et al., 2012).
The Two-quit BENESCO model follows a simulated cohort of 1000
Belgian smokers from ﬁrst quit attempt through retreatment among
those who were initially not successful or who relapsed, until all mem-
bers of the cohort have either died or reached the age of 100 (Fig. 1).
Lifetime clinical and economic outcomes of an initial quit attempt
with varenicline followed by retreatmentwith varenicline, if the patient
fails with or relapses after initial treatment (=2QA varenicline) are
simulated and compared with the alternative interventions:
• 1 quit attempt with nicotine replacement therapy (NRT) followed by
NRT retreatment in case of failure or relapse (=2QA NRT)
• 1 quit attempt with bupropion followed by bupropion retreatment in
case of failure or relapse (=2QA bupropion)
• 1 quit attempt with placebo followed by placebo retreatment in case
of failure or relapse (=2QA placebo)
• Only 1 quit attempt with varenicline followed by 1 quit attempt with
placebo (1QA varenicline).
As in the initial BENESCOmodel, this model allows transitions to the
smoking-related diseases as described in Fig. 2. A cycle length of oneIn Year 2+
In Year 1
Baseline
Smoker
Attempting to Quit / using 
Smoking Cessation 
Intervention 
Quitters
Quit N
Fig. 1. Schematic diagram of three-stage procyear was chosen because the abstinence rate is measured at 1 year in
the clinical trials. Moreover, the beneﬁts of smoking cessation interven-
tions are apparent only up to several years after cessation, whichmakes
a shorter cycle length not useful. All subjects entering the model are
smokers, with co-morbidities according to their baseline prevalence
among smokers. In the ﬁrst year, subjects in the cohort receive initial
smoking cessation treatment. At the endof each year, subjects transition
between 3 smoking states (smoker, recent quitter, long term quitter),
each ofwhich can be further deﬁned in terms of the presence or absence
of the mentioned smoking-related diseases.
Subjects are considered recent quitters if abstinent for 2–5 years
after successful quit attempt and long term quitters after more than
5 years of abstinence. Health beneﬁts of cessation are applied to all
quitters, although risk of relapse remains (Feenstra et al., 2005; van
Genugten et al., 2003). Furthermore all subjects who fail during ﬁrst
quit attempt or relapse after ﬁrst quit attempt will attempt a second
quit. The evaluation of treatment failure or relapse occurs at the end of
each cycle.
Fig. 2 illustrates the order of the smoking-related diseases in the
BENESCO model. By modeling the morbidities in this way, a patient
can have, for example, one or more asthma exacerbations, followed by
CHD or stroke with one or more acute events, followed by lung cancer
or COPD. Death can occur at any time, and its cause is speciﬁed. If sub-
jects have one of the two acutemorbidities (CHD or stroke) they cannot
develop the other. Similarly if subjects develop one of the two chronic
complications (lung cancer or COPD) they cannot develop the other.
Subjects can progress from an acute disease to chronic, but not the
other way. If subjects progress from an acute disease to a chronic one,
their acute disease is ignored from that point forward.Health data input
The abstinence rates of the various smoking cessation interventions
were derived from a recent Cochrane systematic review (Cahill et al.,
2013) as well as from the results of the randomized clinical trial on
varenicline treatment/retreatment. In the absence of efﬁcacy data of
NRT and bupropion at 52 weeks in retreatment trials, we have conser-
vatively used the same value in the retreatment as in the ﬁrst treatment
for these 2 interventions. As in the initial BENESCO model, the current
model does not consider the adverse events related to the SC interven-
tions because clinical trial data do not indicate sustained comparative
difference between interventions that would impact on outcomes.
The clinical data are shown in Table 1.ot Quit
Second quit attempt
Relapse
ess of quitting and relapsing to smoking.
Fig. 2. Graphical presentation of the health economic model.
191L. Annemans et al. / Preventive Medicine Reports 2 (2015) 189–195The annual relapse rate for abstinent subjects is 6% (Wetter et al.,
2004), and this rate is applied to recent quitters each year in the period
of 2–5 years. If after 5 years the subject is still abstinent, then the risk of
relapsing to smoking is reduced to 2% annually for the next 5 years
(years 6–10) (Krall et al., 2002). In the subjects thatmaintain abstinence
through 10 years following their quit attempt, the relapse rate is
reduced to 1% annually.
The hazard ratios of dying from smoking-related diseases (Thun
et al., 2000) have been used as a proxy for the relative risk (RR) of the
incidence and prevalence of smoking-related diseases (Howard et al.,
2008; Orme et al., 2001). The RRs vary with age, gender and smoking
status, as in the analysis by Thun et al. (2000) already used for the initial
BENESCO model (Table 2).
The RR of smoking-related diseases for subjects who remain
smokers at the end of the cycle is assumed to be the same as that of a
current smoker. The RRs of a recent quitter are assumed to be equal to
RRs of former smokers and RRs of long-term quitters are assumed toTable 1
Clinical input data.
SC interventions Efﬁcacy (CAR 9–52 weeks) Source Comm
Efﬁcacy of smoking cessation interventions 1st line
Varenicline 1st line 21.1% Cahill et al. (2013)
Nides et al. (2008)
The r
is app
Bupropion 1st line 15.7% Cahill et al. (2013)
Nides et al. (2008)
The r
is app
NRT 1st line 14.9% Cahill et al. (2013)
Nides et al. (2008)
The r
is app
Placebo 1st line 9.3% Nides et al. (2008) Poole
Efﬁcacy of smoking cessation interventions 2nd line
Varenicline 2nd line 20.1% Gonzales et al. (2014) CAR a
Bupropion 2nd line 15.7% Assumption Assum
NRT 2nd line 14.9% Assumption Idem
Placebo 2nd line 3.3% Phase IV CSR CAR i
CAR = continuous abstinence rate.
CSR = clinical study report (Pﬁzer data on ﬁle).be equal to RRs of never-smokers. The lung cancer risk for long-term
quitters has been kept equal to the risk in recent quitters over lifetime.
The transition probabilities to smoking-related diseases have been
calculated, by smoking status, based on these RRs and the prevalence,
incidence and mortality cases of each smoking-related disease by age
and gender.
Cost data input
Hospitalization costs of smoking-related diseases were obtained
from the Belgian TCT database (2010, tct.fgov.be). This national data-
base provides the average cost per hospital stay for all APR-DRGs (All
Patients Reﬁned Diagnosis Related Group) paid by the public health in-
surance and the patient (co-payment).
The annual follow-up cost for smoking-related diseases was taken
from literature (Annemans et al., 2003; Muls et al., 1998; Pacolet et al.,
2011; Caekelbergh et al., 2005).ents
elative effect of varenicline in comparison to placebo is 2.27 (Cahill et al.). This effect
lied to the efﬁcacy of placebo from Nides et al. (2008) (9.3% ∗ 2.27 = 21.1%).
elative effect of bupropion in comparison to placebo is 1.69 (Cahill et al.). This effect
lied to the efﬁcacy of placebo from Nides et al. (2008) (9.3% ∗ 1.69 = 15.7%).
elative effect of NRT in comparison to placebo is 1.60 (Cahill et al.). This effect
lied to the efﬁcacy of placebo from Nides et al. (2008) (9.3% ∗ 1.60 = 14.9%).
d estimate of Phase III trials comparing varenicline to bupropion and placebo
t 52 weeks
ed equivalent to 1st quit attempt
n 9–52 weeks (secondary endpoint)
Table 2
Relative risks for complications associated with smoking (never smokers = 1).
Population RR of disease Source
Current smokers Former smokers
Chronic obstructive pulmonary disease
Males 18–34 years 1.0 1.0 Thun et al. (2000)
Males 35–64 years 10.8 7.8
Males 65+ years 10.8 7.8
Females 18–34 years 1.0 1.0
Females 35–64 years 12.3 8.9
Females 65+ years 12.3 8.9
Lung cancer
Males 18–34 years 1.0 1.0 Thun et al. (2000)
Males 35–64 years 21.3 8.3
Males 65+ years 21.3 8.3
Females 18–34 years 1.0 1.0
Females 35–64 years 12.5 4.8
Females 65+ years 12.5 4.8
Coronary heart disease
Males 18–34 years 1.0 1.0 Thun et al. (2000)
Males 35–64 years 2.6 1.6
Males 65+ years 1.5 1.2
Females 18–34 years 1.0 1.0
Females 35–64 years 3.2 1.4
Females 65+ years 1.7 1.4
Stroke
Males 18–34 years 1.0 1.0 Thun et al. (2000)
Males 35–64 years 2.4 1.0
Males 65+ years 1.5 1.0
Females 18–34 years 1.0 1.0
Females 35–64 years 3.8 1.5
Females 65+ years 1.6 1.2
Asthma exacerbations
Males 18–34 years 1.4 1.0 Cassino et al. (1999)
Males 35–64 years 1.0 1.0
Males 65+ years 1.1 1.0
Females 18–34 years 1.4 1.0
Females 35–64 years 1.0 1.0
Females 65+ years 1.1 1.0
192 L. Annemans et al. / Preventive Medicine Reports 2 (2015) 189–195Drug costs were taken from the RIZIV/INAMI database for
reimbursed drugs (www.riziv.fgov.be) , and from the CBIP (Centre
Belge d'Information Pharmacothérapeutique) for non-reimbursed
drugs, in 2013. The mean daily cost of the NRTs was estimated basedTable 3
Cost data.
Cost of therapy
Therapy Cost per quit attempt (€) S
Varenicline (Champix) 246.81 w
w
NRT 230.77
Bupropion (Zyban) 170.40 w
w
Cost of smoking-related diseases
Diseases Cost 1st year (€) F
Stroke 16,501€ (8,651€ hospital stay + 7,850€ for
1st year follow-up)
CHD (myocardial infarction & angina) 8,487€ (4,395€ hospital stay + 4,091€ for
1st year follow-up)
Asthma exacerbations 2,861€
COPD 2,186€
Lung cancer 10,765€ 1on a mean daily intake from the ‘Fiche de Transparence June 2008’ on
the CBIP website (www.cbip.be). A mean treatment duration of
12 weeks was applied.
Cost inputs and their sources were validated through discussion
with a group of Belgian clinicians during an Advisory Board: in particu-
lar, agreement was reached on data source for average daily intake and
duration of the smoking cessation interventions.
All costs fromyears prior to 2013were inﬂatedwith thehealth index
of December 2013 (www.mineco.fgov.be). Discount rates of 3% and
1.5% were applied to future costs and health beneﬁts, consistent with
Belgian guidelines (Cleemput et al., 2012).
Cost data are reported in Table 3.
Utilities
To calculate QALYs (Quality Adjusted Life Years), the BENESCO
model utilizes utility weights for smoking-related diseases. For COPD
and lung cancer, utility weights were applied for the ﬁrst year and for
subsequent years. For CHD, stroke, and asthma exacerbations, each ini-
tial and subsequent event leads to a utility decrease in only the cycle
that the event occurs (Table 4).
The baseline utility values for the general population and the utility
weights for the smoking-related diseases were the same as those
reported in the Belgian customization of initial BENESCO model
(Annemans et al., 2009).
Sensitivity analysis
One-way univariate sensitivity analyses and a probabilistic sensitiv-
ity analysis (PSA) were performed. The latter included uncertainty
around effectiveness, costs of complications, and utilities. Time horizon,
population characteristics and model settings were kept constant.
Probability distributions are selected based on the speciﬁc parameter
type according to standard practice (Gray et al., 2010).
The parameters along with the distribution used are shown in the
Technical Appendix A.
Model validation
Quality assurance was conducted for all structural changes made
to the original BENESCO model, as well as for scenario testing and face
validity checks of model results.ource Comments
ww.cbip.be
ww.inami.fgov.be
Based on public price of titration pack (2 weeks) and
10 week pack
Based on a weighted daily cost of 2.75€ times 84 days
ww.cbip.be
ww.inami.fgov.be
Based on public price of 2 packs of 18 days and 1 pack
of 50 days
ollow-up cost per year (€) Source
4,419€ Acute: mean APR-DRG 045/046 (inﬂated year 2010)
(www.tct.fgov.be)
Follow-up: Annemans et al. (2003), inﬂated
2,148€ Acute: mean APR-DRG 190 (MI) & 202 (angina),
inﬂated year 2010
(www.tct.fgov.be)
Follow-up: Annemans et al. (2003), inﬂated
Acute: APR-DRG 141, inﬂated year 2010
http://www.tct.fgov.be
2,186€ Mean annual cost Caekelbergh et al. (2005), inﬂated
0,765€ Mean annual cost Pacolet et al. (2011)
Table 4
Utilities associated with smoking- related diseases.
Smoking-related diseases Utility ﬁrst year Utility subsequent years Source
Chronic obstructive pulmonary disease 0.76 0.76 (Mannino et al. (2003); Spencer et al. (2005))
Lung cancer 0.61 0.50 Trippoli et al. (2001)
For ﬁrst event For subsequent event
Coronary heart disease 0.76 0.76 Hay and Sterling (2005)
Stroke 0.74 0.15 (Duncan et al. (2000); Gage et al. (1998); Tengs and Lin (2003))
Asthma exacerbation 0.52 0.52 Szende et al. (2004)
Table 5
Results.
2QA varenicline compared with
Costs (000€) 2QA
NRT
2QA
bupropion
2QA
placebo
1QA
varenicline
COPD cost −160 −137 −416 −239
Lung cancer cost −28 −24 −74 −42
CHD cost −63 −54 −165 −94
Stroke cost −43 −37 −112 −64
Total difference in smoking-related
disease cost
−295 −251 −766 −440
Total difference incl. drug cost −275 −118 −316 −237
Effects
QALYs 74 63 193 111
LYs 56 48 146 84
QA: quit attempt; COPD: chronic obstructive pulmonary disease; CHD: coronary heart
disease (myocardial infarction and angina); NRT: nicotine replacement therapy; QALY:
quality-adjusted life year; and LY: life year.
193L. Annemans et al. / Preventive Medicine Reports 2 (2015) 189–195This validation process was conducted by PAREXEL-HERON,
developer of the initial BENESCO model and this Two-quit update.
Results
The base case results are shown in Table 5.When compared to other
treatment/retreatment interventions, varenicline retreatment (2QA)
provides both the greatest health beneﬁts (QALYs gained) as well as
cost savings in the long term. For 1000 smokers willing to quit smoking,
2QA varenicline saves respectively 275,000€, 118,000€, 316,000€ and
237,000€ as compared to two courses of NRT (2QA), bupropion (2QA),
placebo (2 QA placebo) or one single varenicline (1QA varenicline)
treatment at lifetime. The number of QALYs gained is 74, 63, 193 and
111 respectively.
In univariate sensitivity analyses, discount rates (from 0% up to 5%
on both costs and effects), cost of NRT and relative risk for smoking-
related diseases in long term quitters were the most inﬂuential param-
eters, though changes did not affect the conclusions. The probabilistic
sensitivity analysis illustrated in Fig. 3 provides evidence for the robust-
ness of the model results.
Discussion
The current analysis assesses the cost-effectiveness of a quit attempt
with varenicline followed by a retreatment with varenicline in the
motivated smoker who failed or relapsed after at least one year since
initial treatment. This intervention has been compared with: (1) 1
quit attempt with NRT followed by retreatment with NRT, (2) 1 quit
attempt with bupropion followed by retreatment with bupropion,
(3) 1 quit attempt with placebo followed by retreatment with placebo,
and (4) only 1 quit attempt with varenicline.
The effectiveness of varenicline treatment/retreatment translates
into beneﬁts of reduced incidence of smoking-related diseases and
deaths, and increased cumulative Life Years and Quality Adjusted Life
Years. These gains are most impacted by avoiding morbidity, especially
due to a predicted reduction of COPD incidence, and avoidingmortality,
primarily due to COPD and lung cancer. The decreased incidence of
smoking-related diseases translates into additional health care savings,
which largely offset the cost associated with varenicline treatment.
The model outcomes suggest net saving and net health beneﬁts for
2QA varenicline over lifetime, making it a cost-saving intervention.
This ﬁnding results from the higher efﬁcacy of varenicline compared
to the other smoking cessation interventions.
This analysis is the ﬁrst one to consider adaptation of the BENESCO
model with a second quit attempt. The initial BENESCO model has been
customized for many countries, leading to similar outcomes based on
same comparators and time horizon (Keating and Lyseng-Williamson,
2010; Zimovetz et al., 2011; Mahmoudi et al., 2012). We might expect
similar conclusions when considering 2QA varenicline in other settings.
However, this needs to be further conﬁrmed.
The study limitations should be noted. First, only the efﬁcacy of the
smoking cessation interventions is considered, with no consideration
of the impact of possible adverse events. However, the earlier
mentioned meta-analysis of available published data has shown thatthe likelihood of adverse events associated with varenicline, NRT
and bupropion is very limited (Cahill et al., 2013) and consequently
their impact on utilities and costs should be minimal. The good cardio-
vascular and neuropsychiatric safety proﬁle of varenicline has also re-
cently been conﬁrmed in clinical trials (Ware et al., 2013; Gibbons and
Mann, 2013; Mills et al., 2014).
Secondly, similar to the initial BENESCO model, this model only in-
cludes 5 smoking-related diseases keeping co-morbidities to a mini-
mum. Modeling all the possible multiple-disease risks and scenarios
would not only greatly increase the complexity of the model but
would also increase the quantity of data required. This more simpliﬁed
model is a conservative approach because it captures only ﬁve smoking-
related diseases with a high impact to the healthcare system, and does
not vary the risks of other diseases based on subjects' morbidity history.
Thirdly, all RRs for smoking-related diseases, as derived from Thun et al.
(2000) have been kept constant for each smoking status. This may be
perceived, in some cases, as a simpliﬁcation of reality. As such, the
model considers that long term quitters (namely quitter for more than
5 years) beneﬁt from constant former smokers' RR for lung cancer as
from year 6 until their death. Peto et al. (2000) described a more pro-
gressive decrease in the risk of lung cancer as the time of abstinence in-
creases. Yet, comparing our input valueswith the values referred in Peto
et al. (2000), our outcomes are more conservative. This assumption has
also been tested in the deterministic and probabilistic sensitivity
analyses.
Other published studies have examined the cost-effectiveness of
varenicline for smoking cessation in the Belgian population, using the
same model as the one on which the current one is built (Annemans
et al., 2009; Bolin et al., 2009; Knight et al., 2012; Wilson et al., 2010).
The key way in which these studies differ from the present analysis is
the number of quit attempts over the subjects' lifetime: previous studies
only considered one quit attempt, while the present analysis considers
up to two quit attempts with the same intervention.
The published studies also differ from the current analysis in terms
of the clinical data sources used, in particular the efﬁcacy data of the in-
terventions. Annemans and colleagues (2009) obtained 52 week
A) 2QA varenicline vs 2QA NRT
B) 2QA varenicline vs 2QA bupropion
C) 2QA varenicline vs 2QA placebo
D) 2QA varenicline vs 1QA varenicline
Fig. 3. Probabilistic sensitivity analysis based on 1000 replications.
194 L. Annemans et al. / Preventive Medicine Reports 2 (2015) 189–195abstinence rates for varenicline, bupropion, and placebo from pooling
the results of two comparative trials (Gonzales et al., 2006; Jorenby
et al., 2006). Bolin and colleagues (2009) derived efﬁcacy data from a
single randomized open-label trial that compared varenicline to NRT
(Aubin et al., 2008). Knight et al. (2012) derived efﬁcacy data from anRCT that compared a standard course of treatment with an additional
12 week maintenance course (Tonstad et al., 2006). The current study
used efﬁcacy data from a large systematic review and meta-analysis
that considered 267 studies (not all for the interventions considered
in the current analysis) to derive the ﬁrst quit attempt efﬁcacies of all
SC interventions (Cahill et al., 2013). These studies all provide similar
cost-effectiveness results, namely that varenicline dominates NRT,
bupropion and placebo, meaning it is less costly and more effective
over time. These ﬁndings are expected given the greater efﬁcacy in quit-
ting of varenicline over the other smoking cessation interventions.
Models are always a simple reﬂection of reality and subject to
uncertainties. In order to assess the uncertainty in the current model
parameters, a PSA was performed where the parameters such as the
effectiveness of the smoking cessation interventions, the treatment
costs of diseases, and the utilities associated with each health state
were varied according to established distributions (Gray et al., 2010).
For every treatment comparison, the PSA results conﬁrmed that
varenicline signiﬁcantly dominated, meaning it was less costly and
more effective than the comparator. The same conclusion was drawn
based on one way sensitivity/scenario analyses on discount rate (from
0% up to 5% on both costs and effects), cost of NRT and relative risk for
smoking-related diseases in long term quitters.
A ﬁnal comment may be related to the perspective of the study
which did not take into account the productivity-related costs, likely
leading to an underestimation of the economic beneﬁts of 2QA
varenicline.Conclusion
Tobacco dependence is a chronic condition and successfully quitting
smoking is extremely difﬁcult. This Two-quit BENESCO model demon-
strates that retreatment with varenicline in case of failure with or
relapse after initial treatment is a cost-saving option versus no
retreatment and versus other retreatment interventions. It supports
the conclusion that fully supporting smokers in their attempts to quit
smoking is an economically justiﬁed strategy.Conﬂict of interest
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